AM is a Group Leader, in vivo pharmacology, and the Cardiovascular Therapeutic Area Lead at Evotec (UK) Ltd. Her work has focused on the prevention and treatment of chronic diseases across the lifespan, in particular cardiovascular, metabolic, and inflammatory diseases. Dr Spiroski currently supports the development of therapeutic candidates, including novel advanced therapy medicinal products (ATMPs), for a variety of disease applications.
